FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240358816> ?p ?o ?g. }

• W4240358816 endingPage "v179" @default.
• W4240358816 startingPage "v179" @default.
• W4240358816 abstract "Background: Panitumumab and cetuximab are standards of treatment for chemotherapy-refractory, wild-type KRAS exon 2 mCRC patients. There are limited data on efficacy of these drugs in everyday practice on national level. Methods: Patients enrolled into nationwide Panitumumab/Cetuximab Reimbursement-Access Program ongoing in Polish cancer centres. All reported patients were included to analyses from April 2012 to December 2015. Key inclusion criteria to the program: mCRC, refractory to chemotherapy (5FU, oxaliplatin, irinotecan), wild-type KRAS exon 2 tumour status, measurable disease, ECOG performance status 0-2. Inclusion and exclusion criteria were the same for panitumumab and cetuximab therapy in all centres. Pre-planned, uniform schedule of efficacy assessment (every 12 weeks) was applied from start of therapy in all centres. Individual patients data concerning efficacy outcome measures were entered prospectively via electronic system into databases of public, national payer - National Health Fund (NFZ). We performed retrospective analysis using Kaplan-Meier method to assess overall survival (OS) and progression-free survival (PFS). Objective response rate (ORR) was also reported. Results: As of April 2012, 2425 patients were enrolled into the program in 62 cancer centres (1527 patients received panitumumab and 898 received cetuximab). Median follow-up was 17.9 months for panitumumab and 25.3 months for cetuximab. Median OS was 9.9 months (95% CI 9.4-10.5) with panitumumab and 10.2 months with cetuximab (95% CI 9.5-10.9). There was no OS significant difference between groups (p = 0.09). Median PFS was 5.6 months (95% CI 5.5-5.7) with panitumumab (n = 1124) and 5.2 months (95% CI 4.9-5.4) with cetuximab (n = 619). There was no PFS difference between groups (p = 0.16). ORR was 16% in panitumumab and 13% in cetuximab group. Conclusions: Panitumumab and Cetuximab provide similar efficacy outcomes in everyday practice in one health care system. Reimbursement, centralized drug-access programs may serve as a source of data for survival analysis on national level. Legal entity responsible for the study: Military Institute of Medicine, Warsaw National Health Fund, Poland Funding: None Disclosure: M. Swierkowski: Consulting role with Pfizer. C. Szczylik: Consulting role with Bayer, Pfizer, Ipsen. All other authors have declared no conflicts of interest." @default.
• W4240358816 created "2022-05-12" @default.
• W4240358816 creator A5032567668 @default.
• W4240358816 creator A5033653267 @default.
• W4240358816 creator A5044127088 @default.
• W4240358816 creator A5049768313 @default.
• W4240358816 creator A5053979974 @default.
• W4240358816 creator A5060641990 @default.
• W4240358816 date "2017-09-01" @default.
• W4240358816 modified "2023-10-14" @default.
• W4240358816 title "Efficacy of panitumumab and cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC): Retrospective analysis of data from nationwide drug-reimbursement-access program" @default.
• W4240358816 doi "https://doi.org/10.1093/annonc/mdx393.054" @default.
• W4240358816 hasPublicationYear "2017" @default.
• W4240358816 type Work @default.
• W4240358816 citedByCount "0" @default.
• W4240358816 crossrefType "journal-article" @default.
• W4240358816 hasAuthorship W4240358816A5032567668 @default.
• W4240358816 hasAuthorship W4240358816A5033653267 @default.
• W4240358816 hasAuthorship W4240358816A5044127088 @default.
• W4240358816 hasAuthorship W4240358816A5049768313 @default.
• W4240358816 hasAuthorship W4240358816A5053979974 @default.
• W4240358816 hasAuthorship W4240358816A5060641990 @default.
• W4240358816 hasBestOaLocation W42403588161 @default.
• W4240358816 hasConcept C121608353 @default.
• W4240358816 hasConcept C126322002 @default.
• W4240358816 hasConcept C143998085 @default.
• W4240358816 hasConcept C167135981 @default.
• W4240358816 hasConcept C2778332735 @default.
• W4240358816 hasConcept C2779998722 @default.
• W4240358816 hasConcept C2780259306 @default.
• W4240358816 hasConcept C2781187634 @default.
• W4240358816 hasConcept C526805850 @default.
• W4240358816 hasConcept C71924100 @default.
• W4240358816 hasConceptScore W4240358816C121608353 @default.
• W4240358816 hasConceptScore W4240358816C126322002 @default.
• W4240358816 hasConceptScore W4240358816C143998085 @default.
• W4240358816 hasConceptScore W4240358816C167135981 @default.
• W4240358816 hasConceptScore W4240358816C2778332735 @default.
• W4240358816 hasConceptScore W4240358816C2779998722 @default.
• W4240358816 hasConceptScore W4240358816C2780259306 @default.
• W4240358816 hasConceptScore W4240358816C2781187634 @default.
• W4240358816 hasConceptScore W4240358816C526805850 @default.
• W4240358816 hasConceptScore W4240358816C71924100 @default.
• W4240358816 hasLocation W42403588161 @default.
• W4240358816 hasOpenAccess W4240358816 @default.
• W4240358816 hasPrimaryLocation W42403588161 @default.
• W4240358816 hasRelatedWork W2010163599 @default.
• W4240358816 hasRelatedWork W2071471252 @default.
• W4240358816 hasRelatedWork W2165225928 @default.
• W4240358816 hasRelatedWork W2508443409 @default.
• W4240358816 hasRelatedWork W2589642515 @default.
• W4240358816 hasRelatedWork W2617055067 @default.
• W4240358816 hasRelatedWork W3000288349 @default.
• W4240358816 hasRelatedWork W3030160958 @default.
• W4240358816 hasRelatedWork W3094547569 @default.
• W4240358816 hasRelatedWork W3180628252 @default.
• W4240358816 hasVolume "28" @default.
• W4240358816 isParatext "false" @default.
• W4240358816 isRetracted "false" @default.
• W4240358816 workType "article" @default.